Expression of ACSL3 was also elevated in a panel of ‘androgen-sensitive’ (LAPC-4, LNCaP, MDA PCa2a, MDA PCa2b, and 22Rv1) versus ‘androgen-insensitive’ (PPC1, PC3, and DU145) prostate cancer cell lines (Zhao et al, 2005; Tomlins et al, 2007). This evidence concerns the gene ACSL3 and prostate cancer.